A new p53 target gene, RKIP, is essential for DNA damage-induced cellular senescence and suppression of ERK activation

Neoplasia (United States)

Volumn 15, Issue 7, 2013, Pages 727-737

  Lee, Su Jin ^a   Lee, Sun Hye ^a   Yoon, Min Ho ^a   Park, Bum Joon ^a  

^a Pusan National University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

BETA GALACTOSIDASE; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLETHANOLAMINE BINDING PROTEIN; PROTEIN P53; SMALL INTERFERING RNA;

ARTICLE; CELL PROLIFERATION; CELL VIABILITY; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; DNA DAMAGE; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; MOUSE; NONHUMAN; ONCOGENE C H RAS; ONCOGENE RAS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SENESCENCE; SIGNAL TRANSDUCTION; WESTERN BLOTTING;

EID: 84879611055     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1593/neo.121862     Document Type: Article

References (62)

1. Cristofalo VJ, Lorenzini A, Allen RG, Torres C, and Tresini M (2004). Replicative senescence: a critical review. Mech Ageing Dev 125, 827-848.
2. Lombard DB, Chua KF, Mostoslavsky R, Franco S, Gostissa M, and Alt FW (2005). DNA repair, genome stability, and aging. Cell 120, 497-512.
3. Balaban RS, Nemoto S, and Finkel T (2005). Mitochondria, oxidants, and aging. Cell 120, 483-495.
4. Mooi WJ and Peeper DS (2006). Oncogene-induced cell senescence-haltingon the road to cancer. N Engl J Med 355, 1037-1046.
5. Irminger-Finger I (2007). Science of cancer and aging. J Clin Oncol 25,1844-1851.
6. Braig M, Lee S, Loddenkemper C, Rudolph C, Peters AH, Schlegelberger B, Stein H, Dörken B, Jenuwein T, and Schmitt CA (2005). Oncogene-inducedsenescence as an initial barrier in lymphoma development. Nature 436, 660-665.
7. Collado M, Gil J, Efeyan A, Guerra C, Schuhmacher AJ, Barradas M, Benguría A, Zaballos A, Flores JM, Barbacid M, et al. (2005). Tumour biology: senescence inpremalignant tumours. Nature 436, 642.
8. Campisi J (2005). Senescent cells, tumor suppression, and organismal aging: goodcitizens, bad neighbors. Cell 120, 513-522.
9. Chen Z, Trotman LC, Shaffer D, Lin HK, Dotan ZA, Niki M, Koutcher JA, Scher HI, Ludwig T, Gerald W, et al. (2005). Crucial role of p53-dependentcellular senescence in suppression of Pten-deficient tumorigenesis. Nature 436, 725-730.
10. Michaloglou C, Vredeveld LC, Soengas MS, Denoyelle C, Kuilman T, van der Horst CM, Majoor DM, Shay JW, Mooi WJ, and Peeper DS (2005).BRAFE600-associated senescence-like cell cycle arrest of human naevi. Nature 436, 720-724.
11. Lazzerini Denchi E, Attwooll C, Pasini D, and Helin K (2005). DeregulatedE2F activity induces hyperplasia and senescence-like features in the mousepituitary gland. Mol Cell Biol 25, 2660-2672.
12. Harris SL and Levine AJ (2005). The p53 pathway: positive and negative feed-back loops. Oncogene 24, 2899-2908.
13. Lavin MF and Gueven N (2006). The complexity of p53 stabilization andactivation. Cell Death Differ 13, 941-950.
14. Tyner SD, Venkatachalam S, Choi J, Jones S, Ghebranious N, Igelmann H, Lu X, Soron G, Cooper B, Brayton C, et al. (2002). p53 mutant mice thatdisplay early ageing-associated phenotypes. Nature 415, 45-53.
15. Maier B, Gluba W, Bernier B, Turner T, Mohammad K, Guise T, Sutherland A, Thorner M, and Scrable H (2004). Modulation of mammalian life span by theshort isoform of p53. Genes Dev 18, 306-319.
16. Cao L, Li W, Kim S, Brodie SG, and Deng CX (2003). Senescence, aging, andmalignant transformation mediated by p53 in mice lacking the Brca1 full-lengthisoform. Genes Dev 17, 201-213.
17. García-Cao I, García-Cao M, Martín-Caballero J, Criado LM, Klatt P, Flores JM, Weill JC, Blasco MA, and Serrano M (2002). Super p53 mice exhibitenhanced DNA damage response, are tumor resistant and age normally. EMBO J 21, 6225-6235.
18. Mendrysa SM, O'Leary KA, McElwee MK, Michalowski J, Eisenman RN, Powell DA, and Perry ME (2006). Tumor suppression and normal aging inmice with constitutively high p53 activity. Genes Dev 20, 16-21.
19. INK4a. Cell 88, 593-602.
20. Ferbeyre G, de Stanchina E, Lin AW, Querido E, McCurrach ME, Hannon GJ, and Lowe SW (2002). Oncogenic ras and p53 cooperate to induce cellularsenescence. Mol Cell Biol 22, 3497-3508.
21. Sun P, Yoshizuka N, New L, Moser BA, Li Y, Liao R, Xie C, Chen J, Deng Q, Yamout M, et al. (2007). PRAK is essential for ras-induced senescence andtumor suppression. Cell 128, 295-308.
22. Courtois-Cox S, Genther Williams SM, Reczek EE, Johnson BW, McGillicuddy LT, Johannessen CM, Hollstein PE, MacCollin M, and Cichowski K (2006).A negative feedback signaling network underlies oncogene-induced senescence. Cancer Cell 10, 459-472.
23. Ventura A, Kirsch DG, McLaughlin ME, Tuveson DA, Grimm J, Lintault L, Newman J, Reczek EE, Weissleder R, and Jacks T (2007). Restoration of p53function leads to tumour regression in vivo. Nature 445, 661-665.
24. Xue W, Zender L, Miething C, Dickins RA, Hernando E, Krizhanovsky V, Cordon-Cardo C, and Lowe SW (2007). Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas. Nature 445, 656-660.
25. Pearson M, Carbone R, Sebastiani C, Cioce M, Fagioli M, Saito S, Higashimoto Y, Appella E, Minucci S, Pandolfi PP, et al. (2000). PML regulates p53 acetylation and premature senescence induced by oncogenic Ras. Nature 406, 207-210.
26. Mayo LD, Seo YR, Jackson MW, Smith ML, Rivera Guzman J, Korgaonkar CK, and Donner DB (2005). Phosphorylation of human p53 at serine 46 determines promoter selection and whether apoptosis is attenuated or amplified. J Biol Chem 280, 25953-25959.
27. Eves EM, Shapiro P, Naik K, Klein UR, Trakul N, and Rosner MR (2006). Rafkinase inhibitory protein regulates aurora B kinase and the spindle checkpoint. Mol Cell 23, 561-574.
28. Marchetti A, Cecchinelli B, D'Angelo M, D'Orazi G, Crescenzi M, Sacchi A, and Soddu S (2004). p53 can inhibit cell proliferation through caspase-mediatedcleavage of ERK2/MAPK. Cell Death Differ 11, 596-607.
29. Crescenzi E, Palumbo G, and Brady HJ (2005). Roscovitine modulates DNArepair and senescence: implications for combination chemotherapy. Clin CancerRes 11, 8158-8171.
30. Vigneron A, Roninson IB, Gamelin E, and Coqueret O (2005). Src inhibitsadriamycin-induced senescence and G2 checkpoint arrest by blocking theinduction of p21waf1. Cancer Res 65, 8927-8935.
31. Rebbaa A, Zheng X, Chu F, and Mirkin BL (2006). The role of histone acetyla-tion versus DNA damage in drug-induced senescence and apoptosis. Cell DeathDiffer 13, 1960-1967.
32. Stefanelli C, Tantini B, Fattori M, Stanic' I, Pignatti C, Clo C, Guarnieri C, Caldarera CM, Mackintosh CA, Pegg AE, et al. (2002). Caspase activation inetoposide-treated fibroblasts is correlated to ERK phosphorylation and both events are blocked by polyamine depletion. FEBS Lett 527, 223-228.
33. INK4a tumor suppressor versus other INK4 family members during mouse development and aging. Oncogene 15, 203-211.
34. Krishnamurthy J, Torrice C, Ramsey MR, Kovalev GI, Al-Regaiey K, Su L, andSharpless NE (2004). Ink4a/Arf expression is a biomarker of aging. J Clin Invest114, 1299-1307.
35. Collado M and Serrano M (2006). The power and the promise of oncogene-induced senescence markers. Nat Rev Cancer 6, 472-476.
36. Bunz F, Dutriaux A, Lengauer C, Waldman T, Zhou S, Brown JP, Sedivy JM, Kinzler KW, and Vogelstein B (1998). Requirement for p53 and p21 to sustainG2 arrest after DNA damage. Science 282, 1497-1501.
37. Vogelstein B, Lane D, and Levine AJ (2000). Surfing the p53 network. Nature 408, 307-310.
38. Lowe SW, Cepero E, and Evan G (2004). Intrinsic tumour suppression. Nature 432, 307-315.
39. Ueda K, Arakawa H, and Nakamura Y (2003). Dual-specificity phosphatase 5(DUSP5) as a direct transcriptional target of tumor suppressor p53. Oncogene 22,5586-5591.
40. Wei CL, Wu Q, Vega VB, Chiu KP, Ng P, Zhang T, Shahab A, Yong HC, Fu Y, Weng Z, et al. (2006). A global map of p53 transcription-factor binding sites inthe human genome. Cell 124, 207-219.
41. Yeung K, Seitz T, Li S, Janosch P, McFerran B, Kaiser C, Fee F, Katsanakis KD, Rose DW, Mischak H, et al. (1999). Suppression of Raf-1 kinase activity andMAP kinase signalling by RKIP. Nature 401, 173-177.
42. Campisi J (2004). Fragile fugue: p53 in aging, cancer and IGF signaling. Nat Med10, 231-232.
43. Blaydes JP and Hupp TR (1998). DNA damage triggers DRB-resistant phosphor-ylation of human p53 at the CK2 site. Oncogene 17, 1045-1052.
44. Shieh SY, Taya Y, and Prives C (1999). DNA damage-inducible phosphorylationof p53 at N-terminal sites including a novel site, Ser20, requires tetramerization. EMBO J 18, 1815-1823.
45. Shieh SY, Ahn J, Tamai K, Taya Y, and Prives C (2000). The human homologsof checkpoint kinases Chk1 and Cds1 (Chk2) phosphorylate p53 at multipleDNA damage-inducible sites. Genes Dev 14, 289-300.
46. Wallace M, Coates PJ, Wright EG, and Ball KL (2001). Differential post-translational modification of the tumour suppressor proteins Rb and p53 modulatethe rates of radiation-induced apoptosis in vivo. Oncogene 20, 3597-3608.
47. V600E-induced lung tumors. Genes Dev 21, 379-384.
48. Sarkisian CJ, Keister BA, Stairs DB, Boxer RB, Moody SE, and Chodosh LA (2007). Dose-dependent oncogene-induced senescence in vivo and its evasionduring mammary tumorigenesis. Nat Cell Biol 9, 493-505.
49. Dhomen N, Reis-Filho JS, da Rocha Dias S, Hayward R, Savage K, Delmas V, Larue L, Pritchard C, and Marais R (2009). Oncogenic Braf induces melanocytesenescence and melanoma in mice. Cancer Cell 15, 294-303.
50. Fu Z, Smith PC, Zhang L, Rubin MA, Dunn RL, Yao Z, and Keller ET (2003).Effects of raf kinase inhibitor protein expression on suppression of prostatecancer metastasis. J Natl Cancer Inst 95, 878-889.
51. Keller ET, Fu Z, and Brennan M (2005). The biology of a prostate cancer metas-tasis suppressor protein: Raf kinase inhibitor protein. J Cell Biochem 94, 273-278.
52. Lee HC, Tian B, Sedivy JM, Wands JR, and Kim M (2006). Loss of Raf kinase inhibitor protein promotes cell proliferation and migration of human hepatomacells. Gastroenterology 131, 1208-1217.
53. Chatterjee D, Bai Y, Wang Z, Beach S, Mott S, Roy R, Braastad C, Sun Y, Mukhopadhyay A, Aggarwal BB, et al. (2004). RKIP sensitizes prostate and breastcancer cells to drug-induced apoptosis. J Biol Chem 279, 17515-17523.
54. Hagan S, Al-Mulla F, Mallon E, Oien K, Ferrier R, Gusterson B, García JJ, andKolch W (2005). Reduction of Raf-1 kinase inhibitor protein expression correlates with breast cancer metastasis. Clin Cancer Res 11, 7392-7397.
55. Al-Mulla F, Hagan S, Behbehani AI, Bitar MS, George SS, Going JJ, García JJ, Scott L, Fyfe N, Murray GI, et al. (2006). Raf kinase inhibitor protein expression in a survival analysis of colorectal cancer patients. J Clin Oncol 24, 5672-5679.
56. Chatterjee D, Sabo E, Tavares R, and Resnick MB (2008). Inverse associationbetween Raf kinase inhibitory protein and signal transducers and activators of transcription 3 expression in gastric adenocarcinoma patients: implications for clinical outcome. Clin Cancer Res 14, 2994-3001.
57. Wang J, Yang YH, Wang AQ, Yao B, Xie G, Feng G, Zhang Y, Cheng ZS, Hui L, Dai TZ, et al. (2010). Immunohistochemical detection of the Raf kinase inhibitorprotein in nonneoplastic gastric tissue and gastric cancer tissue. Med Oncol 27, 219-223.
58. Hu CJ, Zhou L, Zhang J, Huang C, and Zhang GM (2011). Immunohistochemical detection of Raf kinase inhibitor protein in normal cervical tissue andcervical cancer tissue. J Int Med Res 39, 229-237.
59. D'Orazi G, Cecchinelli B, Bruno T, Manni I, Higashimoto Y, Saito S, Gostissa M, Coen S, Marchetti A, Del Sal G, et al. (2002). Homeodomain-interacting proteinkinase-2 phosphorylates p53 at Ser 46 and mediates apoptosis. Nat Cell Biol 4, 11-19.
60. Hofmann TG, Möller A, Sirma H, Zentgraf H, Taya Y, Dröge W, Will H, and Schmitz ML (2002). Regulation of p53 activity by its interaction withhomeodomain-interacting protein kinase-2. Nat Cell Biol 4, 1-10.
61. Taira N, Nihira K, Yamaguchi T, Miki Y, and Yoshida K (2007). DYRK2is targeted to the nucleus and controls p53 via Ser46 phosphorylation in the apoptotic response to DNA damage. Mol Cell 25, 725-738.
62. Chang YS, Lee KY, Lee SH, Koh SH, Hong SW, and Chi SG (2007). Expression and mutation analysis of RKIP (Raf-1 kinase inhibitor protein) in human gastric cancer. J Korean Surg Soc 73, 121-129.